Torrey Loper

“These results further underscore the poor prognosis associated with untreated aortic stenosis of any severity and provide meaningful insights for the management of this patient population.”Philippe Généreux, MD, FACC Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute and lead author of the study. BACKGROUND Previously, we described a novel AS staging classification […]

Led by Philippe Généreux, MD and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients With Aortic Stenosis Have Substantial Untreated Mortality Risk Across All Levels of Aortic Stenosis Severity, but Aortic Valve Replacement Rates Remain Low Even for Patients With Severe Aortic Stenosis...

Clinical trials are necessary to ensure the safety and efficacy of new therapies, but they can be time-consuming, costly and inefficient to enroll, slowing down access to lifesaving treatment options. The future of faster clinical trials is here.

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community. The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.” Nicholas S. Amoroso, MD Assistant […]

Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation. First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona.

“Over the last five years, new therapies to treat heart failure emerged with promising improvements in survival benefit. This study represents the first time we’ve seen an assessment of ‘5-class’ guideline-directed therapy — up to 4 foundational medication classes plus ICD/CRT-D therapy — for these patients. The next big challenge to overcome is implementing care […]